Tomahawk, WI 08/29/2014 (Basicsmedia) – Plans to begin Safety trials on an Ebola Vaccine by NIH and GlaxoSmithKline plc (ADR) (NYSE:GSK) are reportedly underway according to CNBC’s Meg Tirrell. Healthy volunteers could be used for the trials as early as next month. The announcement is good news as this is the deadliest Ebola outbreak in the recent past, seen by 3,000 cases in West Africa with more than 1,500 deaths reported so far.

NIH and GlaxoSmithKline plc (ADR) (NYSE:GSK) will spearhead the vaccine trials. If successful by the end of the year, the vaccine could be given to infected people especially in West Africa.

“GlaxoSmithKline plc (ADR) (NYSE:GSK) actually saying they got a £2.8 million grant from the Welcome Trust and other organization in the U.K, which will enable it to actually build 10,000 additional doses of this vaccine which it says it will give to the WHO if the trials are positive,” said Mrs. Tirrell.

GlaxoSmithKline plc (ADR) (NYSE:GSK) is planning to produce an additional 10,000 doses for its vaccine so that if successful in the trial stage, it could be made readily available to infected patients.

Another vaccination could also be in the pipeline other than the one being produced by GlaxoSmithKline with NIH saying it will start trials for a compound, sometime in the fall. Most of the stocks in the Ebola portfolio were down in Thursday trading session attributed to news that GlaxoSmithKline plc (ADR) (NYSE:GSK) had taken the pole position with its Ebola trail vaccine. Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) on the other hand was up in the market as reports emerged that it could be a possible take out company.

GlaxoSmithKline opting to produce only 10,000 doses for its vaccine raises questions as to whether it will be successful in the trial stages, considering WHO is reporting that up to 20,000 people might have been infected by the deadly disease. Tirrell believes that 10,000 doses’ is still high as it will only be administered’ to high-risk patients.

“We would only want to vaccinate the really high-risk folks. 10,000 actually seems to me like kind of a lot, especially because they are talking doing it after they just potentially complete a phase one safety study,” said Mrs. Tirrell.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.